A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy — Stella
Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.
(2 sites) China
Jiangsu Province Hospital, Nanjing, Jiangsu Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality
Key details Sponsor
Sichuan Baili Pharmaceutical Co., Ltd.
Collaborators
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Enrollment target
~1,450 participants
Primary completion
October 2031
Age range
18 Years – 75 Years
Last updated January 2026